Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease
NEPTUNUS-1 and NEPTUNUS-2 are the first ever global Phase III trials to demonstrate statistically significant reduction in disease activity for Sjögren's disease1
Ianalumab has the potential to become the first and only targeted treatment approved for patients with Sjögren's disease
Ianalumab was well tolerated and demonstrated a favorable safety profile in Sjögren's disease1,2
Novartis plans to present its data at an upcoming medical congress and submit to health authorities globally
EAST HANOVER, N.J., Aug. 11, 2025 /PRNewswire/ -- Novartis today announced positive top-line results from its Phase III trials evaluating ianalumab (VAY736) in adults with active Sjögren's disease. Both trials met the primary endpoint of demonstrating statistically significant improvements in disease activity1. These results support the potential for ianalumab, a drug with a dual mechanism of action, B-cell depletion and BAFF-R inhibition, to become the first targeted treatment for patients with Sjögren's disease, a chronic, disabling autoimmune disease3,4,5.
"Sjögren's disease is a serious, progressive, systemic autoimmune disease, often unrecognized or misdiagnosed with a significant detrimental impact to quality of life, with very limited treatment options and an established unmet need. Both Phase III trials demonstrate that ianalumab improves disease activity in patients with Sjögren's disease," said Shreeram Aradhye, M.D., President of Development and Chief Medical Officer at Novartis. "These Phase III studies mark a significant milestone. We look forward to engaging with health authorities to discuss these findings in the near future."
The NEPTUNUS pivotal trials achieved the primary endpoint of improving disease activity measured by a reduction in EULAR Sjögren's syndrome disease activity index (ESSDAI), a multi-dimensional disease activity measurement compared to placebo1. Ianalumab was well tolerated and demonstrated a favorable safety profile in Sjögren's disease1,2.
Novartis plans to present the NEPTUNUS-1 and NEPTUNUS-2 data at an upcoming medical meeting and submit ianalumab, which was granted Fast Track Designation by the US Food and Drug Administration (FDA), to health authorities globally6.
About ianalumab Ianalumab (VAY736) is a novel fully human monoclonal antibody being investigated for its potential to treat various B cell-driven autoimmune diseases, including Sjögren's disease, immune thrombocytopenia (ITP), systemic lupus erythematosus (SLE), lupus nephritis (LN), warm autoimmune hemolytic anemia (wAIHA) and diffuse cutaneous systemic sclerosis (dcSSc)3,7-13. Its mechanism of action targets B cells in two ways, namely combining B cell depletion via antibody-dependent cellular toxicity (ADCC) and interruption of BAFF-R mediated signals of B cell function and survival3. In clinical trials, ianalumab showed promising efficacy and a favorable safety profile in Sjögren's disease, systemic lupus erythematosus, and immune thrombocytopenia2,14,15. Ianalumab originates from an early collaboration with MorphoSys AG, a company which Novartis later acquired in 202416.
About NEPTUNUS-1 and NEPTUNUS-2 The Phase III clinical trials, NEPTUNUS-1 and NEPTUNUS-2, are global, multicenter, pivotal studies evaluating the efficacy and safety of ianalumab in patients with Sjögren's disease7,8. These trials were designed to provide comprehensive data on ianalumab's potential as a targeted treatment for Sjögren's disease, in patients with active extraglandular disease3,7,8.
NEPTUNUS-1 is a randomized, double-blind, 2-arm multicenter Phase III trial (N=275) to evaluate the clinical efficacy, safety, and tolerability of ianalumab 300 mg subcutaneous (s.c.) monthly compared with placebo for 52 weeks7. NEPTUNUS-2 is a randomized, double-blind, 3-arm multicenter Phase III trial (N=504) to evaluate the clinical efficacy, safety, and tolerability of ianalumab 300 mg s.c. monthly or every 3 months compared with placebo for up to 52 weeks8.
The primary endpoint was measured by improvements in systemic disease activity using ESSDAI (EULAR Sjögren's syndrome disease activity index)7,8. Patients currently enrolled in NEPTUNUS-1 and NEPTUNUS-2 have been given the opportunity to continue follow-up in these studies or enter a long-term extension trial17.
About Sjögren's disease (previously called Sjögren's syndrome) Sjögren's disease is a systemic, chronic autoimmune disorder that causes inflammation and tissue damage, impacting the entire body4. It primarily affects exocrine glands, leading to excessive dryness, with over 90 percent of patients experiencing dry eyes and dry mouth4,18. The disease is heterogenous, patients experience dryness, fatigue and widespread pain and 30-40 percent of patients will also show extraglandular organ involvement5,19. Extraglandular manifestation can be very diverse and can affect skin, musculoskeletal system, kidneys, lungs and other organs19. The risk of lymphoma is increased in patients with Sjögren's5.
Sjögren's is one of the most prevalent rheumatic autoimmune diseases, affecting approximately 0.25 percent of the population with an estimated 50 percent undiagnosed 20-21. Sjögren's is nine times more common in women than men4. B cell dysfunction plays a significant role in the disease by causing an autoimmune response that leads to inflammation and tissue damage3,4. There are no systemic treatments approved, with only limited symptomatic treatments available to provide temporary and partial symptomatic relief, highlighting the need for effective targeted therapies3.
DisclaimerThis press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "potential," "can," "will," "plan," "may," "could," "would," "investigational," "pipeline," "upcoming," "intends," or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for ianalumab, or regarding potential future revenues from ianalumab. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that ianalumab will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that ianalumab will be commercially successful in the future. In particular, our expectations regarding ianalumab could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.
Reimagine medicine with us: Visit us at https://www.novartis.us and connect with us on LinkedIn US, X/Twitter US and Instagram.
References
Novartis data on file
Bowman S et al, Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled, phase 2b dose-finding trial, Lancet 2022; 399:161-71
Dorner T et al, Safety and Efficacy of ianalumab in patients with Sjögren's disease:52-week results from a randomized, placebo-controlled, phase 2b dose-ranging study, Arthritis and Rheumatology 2025, 77(5):560-570
Negrini S et al, Sjögren's syndrome: a systemic autoimmune disease, Clin Exp Med. 2022; 22(1): 9–25
Mariette, Primary Sjögren's symptoms, New England Journal of Medicine, 2018, 378;10
Ianalumab, Department of Health and Human Services, Fast Track Designation, US Food and Drug Administration, 2025
ClinicalTrials.gov NCT05350072 [Last accessed: August 2025]
ClinicalTrials.gov NCT0539214 [Last accessed: August 2025]
ClinicalTrials.gov NCT05653219 [Last accessed: August 2025]
ClinicalTrials.gov NCT05639114 [Last accessed: August 2025]
ClinicalTrials.gov NCT05126277 [Last accessed: August 2025]
ClinicalTrials.gov NCT05648968 [Last accessed: August 2025]
ClinialTrials.gov NTC06470048 [Last accessed: August 2025]
Phase 2 safety and efficacy of subcutaneous (s.c.) dose ianalumab (VAY736; Anti-BAFFR mAB) administered monthly over 28 weeks in patients with Systemic Lupus Erythematosus (SLE) of moderate-to-severe activity, ACR congress, available at: Phase 2 Safety and Efficacy of Subcutaneous (s.c.) Dose Ianalumab (VAY736; Anti-BAFFR mAb) Administered Monthly over 28 Weeks in Patients with Systemic Lupus Erythematosus (SLE) of Moderate-to-Severe Activity - ACR Meeting Abstracts [Last accessed: August 2025]
A Phase 2 Study of ianalumab in patients with primary immune thrombocytopenia previously treater with at least two lines of therapy, EHA congress, available at: EHA Library - The official digital education library of European Hematology Association (EHA) [Last accessed: August 2025]
Novartis to strengthen oncology pipeline with agreement to acquire Morphosys [AG Press release]. [Press release]. Available at: Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash | Novartis [Last accessed: August 2025]
ClinicalTrials.gov NCT05985915 [Last accessed: August 2025]
Maleki Fischbach M, et al, Manifestations and management of Sjögren's disease, Arthritis Res Ther. 2024;26(1):43
Kerry Gairy et al, Burden of illness among subgroups of px with primary SjD and systemic involvement, Rheumatology 2021, Volume 60, Issue 4, April 2021, Pages 1871–1881
Conrad N, et al, Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 millions individuals in the UK, Lancet. 2023;401(10391):1878-1890
Narváez J et al, Prevalence of Sjögren's syndrome in the general adult population in Spain: estimating the proportion of undiagnosed cases, Sci Rep. 2020;10(1):10627
# # #
Novartis Media Relations
E-mail: media.relations@novartis.com
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.comView original content:https://www.prnewswire.com/news-releases/novartis-announces-both-ianalumab-phase-iii-clinical-trials-met-primary-endpoint-in-patients-with-sjogrens-disease-302526227.html
SOURCE Novartis Pharmaceuticals Corporation
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a minute ago
- Yahoo
In a tough job market for new workers, networking and adaptability can make a difference
NEW YORK (AP) — Growing up as the daughter of immigrants from Jamaica, Stacey Watson didn't see herself in the characters of the books she read. Now 28, she wants to be a book editor who helps promote a more diverse range of story protagonists so her nieces and other young people feel represented. But an entry-level job in publishing has proven elusive. Two years after earning her master's degree, with four internships and several part-time jobs under her belt, Watson hasn't landed a full-time staff position. She lives with her parents in Brooklyn to make ends meet. 'You're hoping every year is the year you can tell your parents, 'I got the full-time job, you don't have to worry about me anymore,'' she said. Watson's experience echoes the difficulties facing many job seekers who are trying to start their careers at a time when economic uncertainty has discouraged employers from adding staff and workers from leaving their jobs. The U.S. unemployment rate for college graduates aged 22 to 27 has outpaced the joblessness rate for the general population since the coronavirus pandemic. Many degree-holders seeking their first jobs report spending months submitting applications. In a tight job market, companies often choose more experienced candidates because they can, said Laura Ullrich, economic research director for job search website Indeed. 'Quit rates are low ... and companies aren't hiring many people. So it's this stagnant environment where there's not a lot of room being created for these new grads.' Below, career experts and candidates who landed jobs share how to persevere in the search. Building your network When some employers are using artificial intelligence to filter through hundreds of resumes, having a connection within a company can help candidates by providing an introduction, experts say. An internship or part-time job can provide a starting point for building relationships with professionals in your chosen field. Alumni networks and professional organizations are other avenues for meeting people. When Jennifer Moglia, 22, was interning in the music business, she made a spreadsheet to record the names of everyone she met during meetings, what they talked about and any interests she shared with them. She then looked them up on LinkedIn, the social networking platform, and requested time to meet one-on-one. 'I typically reached out to pretty much anyone that I had worked with, just to say, 'Hi, I'm interning here. I would love to talk to you about your job if you have 30 minutes,'' Moglia said. 'I would just try to make it as easy as possible for them,' saying, ''If your calendar is up to date, I could find a day and time that works. I can book the room.'' The networking paid off. In the months before her college graduation, Moglia applied for 70 jobs, reaching out to contacts she'd made to ask about vacancies. 'Most of the interviews that I got were for companies that I had connections at," she said. After receiving two offers, Moglia now works as a venue marketing coordinator for Live Nation Entertainment in New York. Keep an open mind Consider looking for jobs outside your college major or ideal career path if there are way more than applicants than open positions in your area of choice. Your skills may be transferable to other fields and positions. 'If you ask a lot of 40-year-olds, they're not working in the exact field they went to college for,' Ullrich said. 'So casting a wide net is smart.' Luke Sutton, 24, who graduated college in 2023 with a degree in dramatic writing, wanted to work in television, but a strike by Hollywood writers halted hiring at studios and production companies as he began his search. Sutton applied for more than 1,000 jobs before getting one as a creative assistant at healthcare advertising agency Patients & Purpose. At times, he felt desperate. The hardest part was hearing nothing after filling out applications. 'My head's sort of like spinning, like I just want to be able to eat. Is that too much to ask?' Sutton recalled. He worked part-time jobs and kept an open mind, putting himself forward for a wide range of positions that involved writing and focusing on jobs with assistant in the title. His current role is not his dream job, but 'I'm one of the lucky ones because I'm doing at least something creative,' Sutton said. Adapting to artificial intelligence As use of artificial intelligence grows, employers are looking for people who understand how to use the technology and incorporate it into workflows, said Efrem Bycer, LinkedIn's head of workforce and climate policy partnerships. Because technology is shifting so rapidly, however, adaptability is also a sought-after skill. 'What employers are going to want to know is, can you work through that change?' Bycer said. Some employers are holding off on hiring entry-level workers because they're finding that some tasks can be done by artificial intelligence, said Betheny Gross, research director at WGU Labs, the innovation arm of Western Governors University, an online school based in Utah. But AI can also be used to help bridge the experience gaps of entry-level candidates. The university is offering virtual internships and apprenticeships that simulate scenarios workers would encounter on a job. 'For the time being, the labor market is going to segment into people who understand what AI can do, are able to use it themselves, and understand the strengths and also limitations of it, and those who do not,' Gross said. Give yourself grace One of the most important things to remember in a prolonged job search is that you're not necessarily the reason it's taking a long time, said Peter Cappelli, a management professor at The Wharton School of the University of Pennsylvania. If new would-be workers are feeling discouraged, 'I think the big thing for them and for their parents is to recognize, this is not your kid's fault.' Securing a job since she was laid off from a nonprofit organization in May has been a brutal process for Aileen Ryan, 23, who has supported herself and helped her mother pay bills since she finished high school. None of her 400 applications has brought an offer. Out of the 70 contacts Ryan sent messages to on LinkedIn, only three replied; one of them wrote, 'I wish I could help, but my best recommendation is to pray.' With her unemployment benefits and student loan deferment set to end in December, Ryan plans to move in with her mom, if she doesn't have a job, ideally in the nonprofit sector, by then. Nevertheless, Ryan keeps going because she has to, she said. 'I know what I have to offer and I've worked really hard to get to this point,' Ryan said. "I also know what I want for myself, and I'm just going to keep going until I get to that." ___ Share your stories and questions about workplace wellness at cbussewitz@ Follow AP's Be Well coverage, focusing on wellness, fitness, diet and mental health at Cathy Bussewitz, The Associated Press
Yahoo
a minute ago
- Yahoo
Self-driving vehicle startup Nuro valued at $6 billion in late-stage funding round
(Reuters) -Self-driving vehicle startup Nuro closed its late-stage funding round on Thursday, raising $203 million at a $6 billion valuation from new investors Uber and Nvidia alongside returning backers. The latest tranche of $97 million follows the $106 million announced in April, which included investors such as T. Rowe Price, Fidelity, and Tiger Global. The company's valuation in the latest funding round is lower than the $8.6 billion it was valued at in 2021, according to Pitchbook data. Many startups that became unicorns during the 2021 funding boom are now raising capital at lower valuations as investors' attention turns toward artificial intelligence. "The change reflects broader market conditions and this is a strong outcome for the current market environment," a Nuro spokesperson said. Nuro has been pushing to scale its self-driving platform and expand commercial partnerships. Founded in 2016, Nuro has pivoted from delivery robots to licensing its Nuro Driver technology for use in robotaxis, commercial fleets, and personal vehicles. Nuro partnered with EV maker Lucid and Uber to launch a global robotaxi service. Uber plans to deploy over 20,000 Lucid Gravity SUVs equipped with Nuro's system across dozens of markets over six years starting in 2026.
Yahoo
a minute ago
- Yahoo
EU-US trade deal does not include wine and spirits, says EU trade chief
BRUSSELS (Reuters) -The EU-U.S. trade deal does not include wine and spirits, European Union Trade Commissioner Maros Sefcovic said on Thursday, adding that the door was not closed to tariff reductions for the sector and others not included in the deal. He made the comments after the European Union and the United States detailed commitments made in a deal reached last month that includes a 15% U.S. tariff on most imports from the bloc, including autos, pharmaceuticals, semiconductors and lumber. "This one we didn't get in. But I can tell you that there is clear commitment from the European Commission to put it on the table", Sefcovic said, referring to wines and spirits. The Distilled Spirits Council of the United States expressed disappointment in a statement. "Without a permanent return to zero-for-zero tariffs on spirits, American distillers do not have the certainty to plan for future export and job growth without the fear of retaliatory tariffs returning", it said. It added that it was "determined to continue engaging with the Trump administration to urge for additional negotiations". Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
